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A B S T R A C T
After reviewing the negative effects of antiepileptic drugs (AEDs) on general health and quality of life, the
Commission on Outcome Measurement from the International League Against Epilepsy (ILAE)
recommended incorporating reliable and valid tools in clinical essays in order to achieve a more
accurate assessment of the subjective adverse effects rate and disease severity when using AEDs.
Purpose: The aim of this study was to correlate the severity of adverse effects of AEDs, with the presence
of anxiety and depression in patients with epilepsy.
Methods: The Spanish version of the Liverpool Adverse Events Proﬁle (LAEP) and the Hospital Anxiety
and Depression Scale (HADS) were applied on 130 consecutive outpatients with epilepsy from the
epilepsy clinic at the Mexico’s National Institute of Neurology and Neurosurgery. A correlation analysis
was carried out to determine if the presence of depression and anxiety was related to the adverse effects
of AEDs. The relation between LAEP scores with other epidemiological variables was also assessed.
Results: Our study found a positive correlation between the LAEP and the HADS scores (p = <0.01).
The most common adverse effects were drowsiness (81.5% [n = 106]), difﬁculty in concentrating (76%
[n = 99]), and nervousness and/or agitation (75% [n = 97]). Female gender, a history of febrile seizures,
persistent seizures and polytherapy were associated with a higher toxicity on LAEP. In our study, age at
epilepsy onset, duration of epilepsy, type of epilepsy and patients’ age were not related to higher LAEP
scores.
Conclusion: Adverse effects to AEDs can be related with the presence of psychiatric disorders such as
anxiety and depression in patients with epilepsy.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
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Epilepsy is one of the most common and severe neurological
diseases in the world. It is also an important cause of mortality and
disability in developing countries. Nearly 85% of the epilepsy load
in the world can be found in developing countries, where the
majority of patients with epilepsy do not receive appropriate
medical care. Epidemiological studies show a higher prevalence
and incidence of this condition in the general population of Latin
American than in the North American countries.1 A recent
population study in a rural Mexican community found a 3.9/
1000 prevalence of epilepsy.2 The prognosis for most patients with
epilepsy is in general good, but up to 30% persist with seizures in
spite of being treated with adequate antiepileptic drugs (AEDs);* Corresponding author at: National Institute of Neurology and Neurosurgery of
Mexico Insurgentes Sur 3817 La Fama Tlalpan, 14269 Me´xico DF, Mexico.
E-mail address: imartinez@innn.edu.mx (I.E. Martı´nez-Jua´rez).
1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2012.06.003this produces important harmful effects in the individual’s health
and quality of life, and it also represents a considerable burden for
society.3 The terms adverse event (AE) or adverse experience are
used interchangeably in order to describe the presence of an
undesirable effect in the patient during pharmacological treat-
ment. An adverse event due to medication, as deﬁned by the Food
and Drug Administration (FDA), means ‘‘any adverse event
associated with the use of a drug in humans, whether or not
considered drug related, including the following: an adverse event
occurring in the course of the use of a drug product in professional
practice or study; an adverse event occurring from drug overdose;
an adverse event occurring from drug withdrawal; and any failure
of expected pharmacological action’’.4
After evaluating the negative effects of AEDs on general health
and quality of life, the Commission on Outcome Measurement
from the International League Against Epilepsy (ILAE) recom-
mended incorporating reliable and valid tools (instruments) in
clinical essays in order to achieve a more accurate assessment of
the subjective AEs rate and disease severity when using AEDs.5vier Ltd. All rights reserved.
B. Go´mez-Arias et al. / Seizure 21 (2012) 588–594 589The main objective of this study was to apply the Spanish
version of the Liverpool Adverse Event Proﬁle (LAEP) in Mexican
patients diagnosed with epilepsy in the Epilepsy Clinic of Mexico’s
National Institute of Neurology and Neurosurgery (NINN) and its
relation to the presence of anxiety and/or depression measured by
The Hospital Anxiety and Depression Scale (HADS).
2. Materials and methods
2.1. Subject selection
LAEP and HADS surveys were applied on 130 consecutive adult
patients (age > 18) diagnosed with epilepsy using the ILAE 1989
classiﬁcation6; patients were clinically assessed at the Epilepsy
Clinic of the NINN from March through September 2011. Patients,
who were illiterate and those who had severe cognitive problems
or had a neurological or mental condition that would not allow
them to ﬁll the evaluation scales were excluded. The study was
ﬁrst approved by the Institute’s Research and Ethics Committees.
2.2. Instrument assessment
2.2.1. Liverpool adverse event proﬁle (LAEP)
The LAEP was developed in England by the Liverpool Group,7 as
an instrument that can be used by patients to measure their
perception of AEs from AEDs. The LAEP questionnaire investigates
complaints over the last four weeks. It consists of 19 items
presented as a checklist of symptoms which they may have
experienced in the last four weeks, and makes use of a Likert type
scale where [1] = never, [2] = seldom, [3] = sometimes and [4] = of-
ten or always. The items in the scale do not mention AED
treatment.
Results can be individually assessed in accordance to the
frequency value, but in some studies the items were added up in
order to obtain a global score. Total individual scores varied from
19 (low side effect prevalence and severity) to 76, which indicates
greater symptom prevalence and severity.8 The Spanish version of
the Adverse Event Proﬁle was validated in 2009 by Carren˜o et al.9
2.2.2. Hospital Anxiety and Depression Scale (HADS)
HADS was applied to assess the presence and severity of
depression and anxiety. This is a 14-item self report screening scale
developed to detect the presence of anxiety and depression
symptoms in the setting of a medical nonpsychiatric outpatient
clinic.10 The HADS scores seven anxiety symptoms and seven
depression symptoms, and each item presents a four-point Likert
type scale: [0] = never; [1] = sometimes, [2] = most of the day,
[3] = almost all day. The maximum score for both scales is 21
points for depression and anxiety each one. Scores adding up to 0–
7 are considered normal, 8–10 indicate mild anxiety and/or
depression and 11 indicates clinically relevant anxiety and/or
depression. The Spanish version was validated by Herrero et al.11
This version has a Cronbach’s alpha coefﬁcient of 0.90 for the full
scale, 0.84 for the depression subscale and 0.85 for the anxiety
subscale. The cut-off point for depressive disorder is 5 (sensitivity
77.8%; speciﬁcity 80.9%), and for anxiety disorder is 8 (sensitivity
89%; speciﬁcity 77.2%).
2.3. Data collection
Socio-demographic data were collected including age, gender,
educational level, employment status, age at seizure onset,
diagnosis (type of epilepsy); persistent seizure type; months free
of any seizure type; seizure freedom (the deﬁnition of the ILAE
consensus by the Commission on Therapeutic Strategies Level 1,12
was used to determine response to treatment; where seizurefreedom was deﬁned as freedom from all types of seizures
including auras or simple partial seizures for 12 months; treatment
failure the outcome whereby the patient did not attain seizure
freedom after an informative trial of an intervention and
undetermined for patients that do not fulﬁll the seizure freedom
or the treatment failure categories, for example patients free of
seizures for at least one month but less than 12 months); family
history of epilepsy, malformation/congenital defect, cerebral
hypoxia, head trauma, febrile seizures, neuroinfection, cerebro-
vascular disease or unknown conditions [none of the former]);
current treatments (including AEDs and use of antidepressant and/
or anxyolitic drugs). Patients were also directly asked if they had
any difﬁculties understanding any of the scales items.
2.4. Statistical analysis
Data were analyzed using the SPSS1 (Statistical Package for
Social Sciences – version 17) software. Central tendency measures
and percentages were used for the descriptive analysis of
continuous and nominal variables, respectively. Comparisons
were established using the x2 test or the exact Fisher test for
categorical variables and Student’s t test or Mann–Whitney U test
for numerical variables. We performed a correlation analysis
(Spearman) between ratings of the LAEP and the anxiety and
depression scores of the HADS. Comparisons between AEDs in
mono and polytherapy, LAEP and HADS scores using Kruskal–
Wallis one-way analysis of variance were also done.
3. Results
3.1. Socio-demographic and clinical characteristics
Data were collected from 130 patients (54% women, [n = 60]);
mean age was 30.6  11.08 years. Regarding educational level, 20.8%
(n = 27) patients had ﬁnished primary school, 24.6% (n = 32) had
attended secondary school, 25.4% (n = 33) had ﬁnished high school
and 29.2% (n = 38) had a college degree. Paid employees constituted
30.8% (n = 40) of the population, 9.2% (n = 12) were unemployed and
36.2% (n = 47) were employed without payment, e.g. housekeepers.
Mean age at seizure onset was 15.0  10.71 years (range 1–65 years).
Mean duration of epilepsy was 15.57 years. Forty three patients
(33.3%) had a family history of epilepsy and 4.5% (n = 9) had
experienced febrile seizures.
Sixty seven patients (51.5%) had cryptogenic epilepsy, 29.2%
(n = 38) had symptomatic epilepsy and 19.2% (n = 25) had
idiopathic epilepsy. Sixteen patients (12.3%) had mesial temporal
lobe epilepsy due to hippocampal sclerosis (MTLE/HS) and in the
analysis were considered cryptogenic. Among patients with
symptomatic epilepsies, 8.5% (n = 11) had congenital malforma-
tion or focal dysplasia, 7.7% (n = 10) had cerebrovascular disease,
6.9% (n = 9) had history of neuroinfection, 3.1% (n = 4) had
neoplasia, 2.3% (n = 3) had phacomatosis and 1% (n = 1) presented
cerebral hypoxia. Six patients with MTLE/HS and eight patients
with neoplasia had had epilepsy surgery. Patients with symptom-
atic epilepsies due to neoplasia and those with persistent seizures
were under study to determine if they were surgical candidates.
Among patients with idiopathic epilepsies, 14.6% (n = 19) patients
had juvenile myoclonic epilepsy, 2.3% (n = 3) had epilepsy with
tonic–clonic seizures on awakening and one patient had juvenile
absence epilepsy.
Two patients were diagnosed with Lennox–Gastaut syndrome,
but had a mild cognitive defect, so they were able to complete the
surveys with the supervision of a relative.
Twenty four patients (18.5%) were seizure free; 68 patients
(52.3%) persisted with seizures and 38 patients (29.2%) were
undetermined regarding seizure control. The persistent seizure
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Fig. 1. Percentage and severity of common adverse effects measured by Liverpool Adverse Events Proﬁle (LAEP).
 r=  0.5 9 
 p=  <0.01 
 n=  130  
 
B. Go´mez-Arias et al. / Seizure 21 (2012) 588–594590types were: complex partial seizures (CPS) in 24.6% (n = 32)
patients, followed by generalized tonic–clonic seizures in 16.2%
(n = 21) patients, simple partial seizures (SPS) in 13.8% (n = 18)
patients, myoclonic seizures in 13.1% (n = 17) patients, secondarily
generalized partial seizures (SGPS) in 8.5% (n = 11) patients,
absence seizures in 1.5% (n = 2) patients and other seizures types
in 4.5% (n = 6) patients.
Sixteen patients (12.3%) received antidepressant or anxyolitic
treatment in a regular manner, without exceeding a 12-month
period of time.
3.2. LAEP and HADS scores
The most common AEs were: drowsiness 81.5% [n = 106]),
difﬁculty in concentrating (76% [n = 99]), nervousness and/or
agitation (75% [n = 97]), memory problems (74% [n = 96]) and
fatigue (73% [n = 95]). The frequency and severity of common AEs
associated with the use of AEDs are shown in (Fig. 1). The average
LAEP score was 41.2  11.8 (SD) with a minimum of 19 and a
maximum of 66. The mean value for the HADS depression subscale
(HADS-D) was 4.56  3.98 (SD), (range 0–19). The mean value for the
HADS anxiety subscale (HADS-A) was 7.40  4.25 (SD), (range 0–21).
Table 1 shows the toxicity rate in the LAEP, using a cut-point
score of <45 for ‘‘low toxicity’’ and 45 for ‘‘high toxicity’’ asTable 1
Hospital Anxiety and Depression Scale (HADS) mean and severity scores and their
correlation with the Liverpool Adverse Events Proﬁle (LAEP) toxicity.
HADS-D
n = 130
LAEP toxicity (n)%
<45 45 p
HADS-D
mean score
(76) 58.4%
3.05  2.77
(54) 41.5%
6.69  4.45
<0.01
Normal (69) 91% (35) 65% <0.01
Mild (6) 8% (9) 17%
Relevant (1) 1.3% (10) 19%
HADS-A
n = 130
LAEP toxicity (n)%
<45 45 p
HADS-A
mean score
(76) 58.4%
5.88  3.38
(54) 41.5%
9.54  4.46
<0.01
Normal (52) 67% (19) 35% <0.01
Mild (17) 22% (14) 26%
Relevant (7) 9% (21) 39%
r=  0.55  
p=  <0.01  
n= 130  
Fig. 2. Correlation between Hospital Anxiety and Depression Scale (HADS) and
Liverpool Adverse Events Proﬁle (LAEP) scores in patients with epilepsy.
B. Go´mez-Arias et al. / Seizure 21 (2012) 588–594 591previously described by Gilliam et al.5 and also shows the
correlation between HADS-D and HADS-A with the toxicity scores
of LAEP where a positive correlation was found between the
depression and anxiety scores from HADS (r = 0.639; p = <0.01). A
positive correlation was also found between the depression
severity score (HADS-D) and the LAEP score (r = 0.55;
p = <0.01); and with the HADS-A score and the LAEP scale rates
(r = 0.59; p = <0.01) (Fig. 2).
3.3. Comparisons between clinical characteristics with LAEP and
HADS subscales (see Table 2)
When LAEP and HADS scores were compared for men and
women, a statistically signiﬁcant difference in gender was
observed, as women had higher toxicity on LAEP score (p = 0.034).
Depression was more frequent in patients with symptomatic
epilepsy, while anxiety was seen more in patients with idiopathic
epilepsy but there were no signiﬁcant differences in LAEP toxicity
scores between patients considering epilepsy etiology (p = 0.089).
No signiﬁcant differences were found when the HADS-D and
HADS-A scores were compared among patients with cryptogenic,
idiopathic and symptomatic epilepsy (p = 0.36 and p = 0.48,
respectively).
Patients with persistent seizures and undetermined regarding
seizure control had signiﬁcantly higher toxicity scores than those
free from all seizures (p = 0.004) whereas HADS-D and HADS-A
scores were not related to seizure freedom (p = 0.256 and p = 0.267,
respectively).
Patients with history of febrile seizures, presented a higher
toxicity LAEP (p = 0.033) compared to those without them; neither
HADS-D nor HADS-A had statistically signiﬁcant differences in this
group (p = 0.58 and p = 0.33, respectively).
No statistically signiﬁcant differences were found regarding
high toxicity measured by LAEP and HADS-D or HADS-A when
considering age at epilepsy onset (p = 0.80; p = 0.51; p = 0.94),
duration of epilepsy (p = 0.153; p = 0.88; p = 0.38) and patients’
current age (p = 0.182; p = 0.91; p = 0.36).Table 2
Comparisons between clinical characteristics with Liverpool Adverse Events Proﬁle (LA
Clinical characteristics LAEP toxicity n (%) p HADS-Anxiety n (%)
<45 45 Normal Mild 
Gender
Female 35 (46.1%) 35 (64.8%) 0.034 32 (45.1%) 16 (51
Male 41 (53.9%) 19 (35.2%) 39(54.9%) 15 (48
Febrile seizures
Present 2 (2.6%) 7 (13%) 0.033 4 (5.6%) 4 (12
Absent 74 (97.4%) 47 (87%) 67 (94.4%) 27 (87
Etiology
Cryptogenic 33 (43.4%) 34 (63%) 0.089 37 (52.1%) 15 (48
Idiopathic 17 (22.4%) 8 (14.8%) 12(16.9%) 5 (16
Symptomatic 26 (34.2%) 12 (22.2%) 22 (31%) 11 (35
Seizure freedom
Seizure free 21 (27.6%) 3 (5.6%) 0.004 18 (25.3%) 3 (9.7
Treatment failure 33 (28.9%) 35 (64.8%) 33 (46.5%) 19 (61
Undetermined outcome 22 (43.4%) 16 (29.6%) 20 (28.2%) 9 (29
Number of AEDs
1 45 (69.2%) 24 (44.2%) 0.032 36 (50.7%) 18 (58
2 17 (22.4%) 12 (22.2%) 21 (29.3%) 3 (9.7
3 14 (18.4%) 13 (24.1%) 13 (1.4%) 6 (19
4 0 (0%) 5 (9.3%) 1 (0.8%) 4 (12
Use of antidepressants or anxyolitcs
Present 5 (6.6%) 11 (79.6%) 0.028 5 (7%) 1 (3.2
Absent 71 (93.4%) 43 (20.4%) 66 (93%) 30 (96
AEDs (antiepileptic drugs).There was a statistically signiﬁcant relation (see Table 2), as
well as a positive correlation between the number of AEDs and
LAEP toxicity scores (r = 0.29; p = 0.001).
Patients taking antidepressants or anxyolitics had higher LAEP
toxicity, HADS-D and HADS-A scores (p = 0.028; p = <0.01;
p = 0.01); 31.3% (n = 5) of these patients had a relevant HADS-D
score and 62.5% (n = 10) had a relevant HADS-A score, nine of these
patients (56.3%) were taking two or three AEDs and only one
patient (6.3%) was completely seizure free, three patients (18.8%)
were undetermined regarding seizure control and 12 patients
(75%) had treatment failure and persisted with seizures.
3.4. Determination of antiepileptic drugs in mono and polytherapy
and their relation to LAEP score
Over half of patients were on AED monotherapy (53.1%
[n = 69]), 22.3% (n = 29) patients received two AEDs, 20.8%
(n = 27) patients used three AEDs, and 3.8% (n = 5) received four
AEDs. Most commonly used AEDs in monotherapy were: valproate
(VPA) in 29 patients, carbamazepine (CBZ) in 15 patients and
phenytoin (PHT) in six patients.
Valproate was the most commonly used AED in polytherapy (40
patients), followed by CBZ in 30 patients, and lamotrigine (LTG) in
18 patients. The most frequent AEDs combinations were:
VPA + CBZ in 6.6% (n = 4) of patients, PHT + CBZ in 6.6% (n = 4)
patients, VPA + CBZ + PHT in 6.6% (n = 4) patients and VPA + LTG in
4.9% (n = 3) patients.
Comparisons between each AED in monotherapy and all AEDs
in polytherapy did not show a statistically signiﬁcant difference in
LAEP score (p = 0.28) and HADS subscales (p = 0.46) as shown in
Fig. 3. Table 3 shows the percentage of use in monotherapy, as well
as in polytherapy of the various AEDs.
When the association between AEs and LAEP scores was studied
for each AED used in mono and polytherapy, tremor produced by VPA
monotherapy was the only AE that showed statistical signiﬁcance
(p = <0.01). Mouth and gum problem was the only AE that showed
statistical signiﬁcance with CBZ polytherapy (p = <0.01).EP) and Hospital Anxiety and Depression Scale HADS) subscales.
 p HADS-Depression n (%) p
Relevant Normal Mild Relevant
.6%) 22 (78.6%) 0.01 52 (50%) 11 (77.3%) 7 (63.6%) 0.145
.4%) 6 (21.4%) 52 (50%) 4 (26.7%) 4 (36.4%)
.9%) 1 (3.6%) 0.337 6 (5.8%) 2 (13.3%) 1 (9.1%) 0.587
.1%) 27 (96.4%) 98 (94.2%) 13 (86.7%) 10 (90.9%)
.4%) 15 (53.6%) 0.48 53 (51%) 6 (40%) 8 (72.7%) 0.36
.1%) 8 (28.6%) 22 (21.2%) 3 (20%) 0 (0%)
.5%) 5 (17.9%) 29 (27.9%) 6 (40%) 3 (27.3%)
%) 3 (10.7%) 0.267 20 (19.2%) 3 (20%) 1 (9.1%) 0.256
.3%) 16 (57.2%) 50 (32.7%) 9 (60%) 9 (81.8%)
%) 9 (32.1%) 34 (48.1%) 3 (20%) 1 (9.1%)
.1%) 15 (53.6%) 0.027 57 (54.8%) 9 (60.1%) 3 (27.3%) 0.402
%) 5 (17.9%) 23 (22.1%) 2 (13.8%) 4 (36.4%)
.4%) 8 (28.6%) 19 (18.3%) 4 (26.7%) 4 (36.4%)
.9%) 0 (0%) 5 (4.8%) 0 (0%) 0 (0%)
%) 10 (37.5%) 0.01 6 (5.8%) 5 (33.3%) 5 (45.5%) <0.01
.8%) 18 (64.3%) 98 (94.2%) 10 (66.7%) 6 (54.5%)
Fig. 3. Comparison between antiepileptic drugs (AEDs) in monotherapy and polytherapy, Liverpool Adverse Events Proﬁle (LAEP) and Hospital Anxiety and Depression Scale
(HADS) subscales total scores.
B. Go´mez-Arias et al. / Seizure 21 (2012) 588–5945924. Discussion
The LAEP scale was used to study common adverse events
produced by AEDs in patients diagnosed with epilepsy who
attended the Epilepsy Clinic in a referral neurological healthcareTable 3
Prescription of antiepileptic drugs (AEDs) in mono and polytherapy.
AEDs Monotherapy % (n=) Polytherapy % (n=) Total % (n=)
CBZ 11.5 (15) 23.1 (30) 34.6 (45)
CLB 0 8.2 (5) 3.8 (5)
CNZ 0.8 (1) 10 (13) 10.7 (14)
DZP 0 0.8 (1) 0.76 (1)
GBP 0.8 (1) 0 0.76 (1)
LEV 7.2 (5) 19.7 (12) 13 (17)
LTG 3.8 (5) 13.8 (18) 17.6 (23)
OXC 3.8 (5) 5.4 (7) 9.2 (12)
PB 0 0.8 (1) 0.76 (1)
PGB 0 1.5 (2) 0.15 (2)
PHT 4.6 (6) 13.1 (17) 17.6 (23)
PMD 0 2.3 (3) 2.3 (3)
TPM 1.5 (2) 13.1 (8) 7.6 (10)
VPA 22.3 (29) 30.8 (40) 53 (69)
PHT (Phenytoin); CBZ (Carbamazepine); VPA (Valproate); OXC (Oxcarbazepine);
PMD (Primidone); CLB (Clobazam); TPM (Topiramate); LEV (Levetiracetam); CNZ
(Clonazepam); LTG (Lamotrigine); PGB (Pregabalin); DZP (Diazepam); GBP
(Gabapentin); PB (Phenobarbital).institution. LAEP scores were correlated with the presence of
anxiety and/or depression using the HADS subscales scores.
Our study found a signiﬁcant correlation between anxiety and/
or depression symptoms severity according to HADS subscales and
high toxicity (45) on LAEP scale in patients with epilepsy
(p = <0.01). Thus, it can be deduced that a higher LAEP score (a
higher AE frequency and severity) can be correlated with the
presence of psychiatric disorders such as anxiety and depression.
Similar ﬁndings have been reported in previous studies using the
LAEP scale.8,9,13,14
Mensah et al.15 studied 515 epilepsy patients that completed
the HADS survey; about 18.9% of these patients had mild anxiety
and 20.5% presented a signiﬁcant disorder. In addition suggested
that a past and current history of depression are the strongest
factors associated with anxiety, and that anxiety disorders
commonly affect patients with epilepsy and can be related to
the disease itself or to other factors such as demographic and social
characteristics. Other studies have estimated that the prevalence
of anxiety disorders in patients with epilepsy ﬂuctuates between
14.8% and 25%.16,17
In our study, the most common AEs were drowsiness (81.5%),
followed by difﬁculty in concentrating (76%), nervousness (75%),
memory problems (74%) and fatigue (73%). These results are
consistent with those of previous studies.18,19 Only 1.5% (2) of
patients did not report any adverse event at all, and none of our
B. Go´mez-Arias et al. / Seizure 21 (2012) 588–594 593patients obtained the maximum score. These results, in accordance
to Carren˜o et al.: ‘‘suggest that this survey covers the occurrence of
the speciﬁc adverse events present in the population under
study’’.9
It must be noticed that some patients had some difﬁculties
differentiating the meaning of item 19 ‘‘sleep disturbances’’ from
the one of item 16 ‘‘drowsiness (being sleepy)’’; when they were
questioned about their interpretation of item 19 some patients
thought they were being asked about having nightmares or
insomnia. It also should be pointed out that the Likert Scale used in
the LAEP lacks an intermediate category between the values
[3] = sometimes and [4] = often or always; this could result in
higher scores in some patients.
The use of the LAEP scale was justiﬁed due to the fact that some
adverse events produced by AEDs, such as diplopia, dysarthria,
mood disorders, headache, dizziness, gastrointestinal disorders,
dermatological problems, and idiosyncratic reactions can easily be
reported by the patient through routine questions; however,
drowsiness, cognitive impairment and sexual dysfunction, hair
changes, nystagmus, claudication, tremor and weight gain or loss
are evident when a standardized questioning method is used.8,20 In
addition, some of the AEs of AEDs, such as difﬁculty in
concentrating, fatigue and sleep disorders, can resemble some
somatic symptoms of depression.21 These confusing factors can
alter the sensitivity and speciﬁcity of a differential tool such as the
LAEP scale, emphasizing the importance of using a concomitant
assessment tool that can clarify these potential confounding
factors.
Neither AED in monotherapy nor AEDs in polytherapy were
associated with a signiﬁcantly higher score on LAEP or HADS
subscales. When AEDs in mono and polytherapy were correlated
with each AEs of the LAEP scale; VPA monotherapy was found to
signiﬁcantly correlate with the presence of tremor, a commonly
side effect described with this AED and CBZ polytherapy
signiﬁcantly correlated with mouth and gum problems possibly
because it was frequently combined with PHT.
Perucca et al.14 reported that seizure onset at a young age;
symptomatic etiology and a history of febrile seizures had a
negative impact on LAEP scores. We found that 77.8% of patients
with febrile seizure presented a LAEP score 45 (p = 0.033),
probably related to drug-resistant temporal lobe epilepsy. We also
found that female gender showed higher LAEP toxicity and HADS-A
score. In our study, age at seizure onset, epilepsy duration and
etiology did not have a statistically signiﬁcant relationship to LAEP
toxicity; a recent study by Martins et al.22 found no differences in
LAEP scores in patients with focal and generalized epilepsies.
Treatment failure or the presence of persistent seizures was
frequent among our patients as we are a referral center and we
used the new ILAE consensus to determine seizure freedom; these
could be the reasons why only 18.5% patients were completely free
of all seizures. Patients with persistent seizures showed higher
LAEP toxicity but interestingly not signiﬁcantly higher scores on
HADS subscales. It could be that patients with persistent seizures
were taking more than one AED thus patients on polytherapy had a
signiﬁcantly higher toxicity on LAEP. Several studies have
suggested a correlation between AED polytherapy and a low
quality of life score in patients with epilepsy.23–25 Although our
patients did not complete a quality of life survey, a positive
correlation was found between the number of AEDs that they
received and the LAEP score. Canevini et al.26 suggested that AEDs’
toxicity is more closely related to the total ‘‘load’’ of the drug (the
sum of all ratios of actually prescribed daily doses and the mean
therapeutic dose of each drug) than to the number of administered
AEDs; however they found no correlation between LAEP and AEDs’
load in a group of patients with drug-resistant epilepsy but a
positive correlation between LAEP and number of AEDs. Theseauthors concluded that ‘‘the current tendency to refuse poly-
therapy because of a concern of increased toxicity is not
warranted’’. They also suggested that the LAEP had a suboptimal
sensitivity as a tool for the detection of differences in the toxicity of
AEDs in varying patient cohorts. Panelli et al.8 did not ﬁnd
statistically signiﬁcant differences when average LAEP scores were
compared in three different groups of patients: without AEDs, with
AEDs, and with recently initiated AED therapy. We consider that
high LAEP scores in our patients in monotherapy might be the
result of the presence of anxiety and/or depression disorders and
possibly a reﬂect of genetic variability; the latter could be
responsible for 20–95% variance in the response to AEDs, and
could also affect the drugs tolerability and safety.27 Unfortunately,
current pharmacological treatment for epilepsy, in contrast with
other therapeutic ﬁelds, is not a ‘‘clearly’’ outlined process in which
a speciﬁc functional o biochemical deﬁcit is corrected, thus,
selecting an AED is an empirical process based on previous clinical
observations made with representative patients,28 as we found
polytherapy can lead to high LAEP toxicity and not necessarily to
seizure freedom.
Kanner et al.29 in a study with 188 patients with an epilepsy
diagnosis, showed that mood disorders and/or anxiety often go
underrecognized and undertreated, considering that up to 64.7% of
symptomatic cases had not received any treatment and only 28% of
patients who received antidepressants were free of symptoms;
about 72% still had some symptoms that were partially due to
suboptimal antidepressant prescription. These ﬁndings are similar
to ours, where 12.3% (n = 16) of patients received antidepressants
or anxyolitics in a regular manner without exceeding the 12-
month treatment course; among these patients 31.3% had a high
HADS-D score and 62.5% had a high HADS-A score; it should be
pointed out that these patients were mainly on AED polytherapy
and most of them persisted with seizures, which could also explain
the high LAEP toxicity seen in this group.
5. Conclusions
The importance of this study lies in the fact that it is the ﬁrst one
to apply the Spanish validated LAEP scale to Mexican patients with
epilepsy and correlates its results to anxiety and depression
symptoms measured with the HADS scale.
Our study was limited by the fact that AEs cannot be assessed
through LAEP in patients that are not able to answer the survey (i.e.
patients with moderate or severe cognitive impairment or patients
who are illiterate), a factor that could cause our results to be biased.
As this was a descriptive cross-sectional study it did not allow the
assessment of AEs when AEDs dosages were changed and/or
antidepressant or anxiolytic drugs were initiated.
The results shown can only be analyzed in terms of relations
and not of causality, because both surveys were applied in a certain
moment during the disease, that is, we cannot determine if anxiety
or depression disorders trigger a certain number of AEs, or if the
presence of AEs has any incidence on the severity of anxiety/
depression. This study was carried out in a highly specialized
hospital, where the majority of the patients presents difﬁcult to
control epilepsies; therefore, our results cannot be extrapolated for
the rest of the Mexican patients with epilepsy.
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